Published in Lancet on July 28, 2007
VRT as a Biomarker of Cerebellar Dysfunction in Chronic Cannabis Use | NCT03662737
The dopamine hypothesis of schizophrenia: version III--the final common pathway. Schizophr Bull (2009) 6.03
Screening, brief interventions, referral to treatment (SBIRT) for illicit drug and alcohol use at multiple healthcare sites: comparison at intake and 6 months later. Drug Alcohol Depend (2008) 5.93
Continued cannabis use and risk of incidence and persistence of psychotic symptoms: 10 year follow-up cohort study. BMJ (2011) 3.84
Psychiatric comorbidities and schizophrenia. Schizophr Bull (2008) 2.69
Should drugs be decriminalised? No. BMJ (2007) 2.55
High-potency cannabis and the risk of psychosis. Br J Psychiatry (2009) 2.41
Impulsivity, attention, memory, and decision-making among adolescent marijuana users. Psychopharmacology (Berl) (2012) 2.36
Incidence of schizophrenia and other psychoses in England, 1950-2009: a systematic review and meta-analyses. PLoS One (2012) 2.33
The therapeutic potential of cannabis and cannabinoids. Dtsch Arztebl Int (2012) 2.31
The global epidemiology and contribution of cannabis use and dependence to the global burden of disease: results from the GBD 2010 study. PLoS One (2013) 2.17
The environment and susceptibility to schizophrenia. Prog Neurobiol (2010) 1.94
Smoked medicinal cannabis for neuropathic pain in HIV: a randomized, crossover clinical trial. Neuropsychopharmacology (2008) 1.94
Risks associated with the non-medicinal use of cannabis. Dtsch Arztebl Int (2015) 1.90
Schizophrenia from a neural circuitry perspective: advancing toward rational pharmacological therapies. J Clin Invest (2009) 1.87
Adverse effects of medical cannabinoids: a systematic review. CMAJ (2008) 1.86
Etiological and clinical features of childhood psychotic symptoms: results from a birth cohort. Arch Gen Psychiatry (2010) 1.85
Schizophrenia. Lancet (2016) 1.83
A randomized, placebo-controlled, crossover trial of cannabis cigarettes in neuropathic pain. J Pain (2008) 1.82
Blurred boundaries: the therapeutics and politics of medical marijuana. Mayo Clin Proc (2012) 1.79
Toxoplasma gondii and other risk factors for schizophrenia: an update. Schizophr Bull (2012) 1.75
Phenotypic Manifestation of Genetic Risk for Schizophrenia During Adolescence in the General Population. JAMA Psychiatry (2016) 1.73
Temporal trends in marijuana attitudes, availability and use in Colorado compared to non-medical marijuana states: 2003-11. Drug Alcohol Depend (2014) 1.70
Reduced cortical cannabinoid 1 receptor messenger RNA and protein expression in schizophrenia. Arch Gen Psychiatry (2008) 1.64
Adolescent cannabis problems and young adult depression: male-female stratified propensity score analyses. Am J Epidemiol (2008) 1.63
Opposite effects of delta-9-tetrahydrocannabinol and cannabidiol on human brain function and psychopathology. Neuropsychopharmacology (2009) 1.62
Psychopathological mechanisms linking childhood traumatic experiences to risk of psychotic symptoms: analysis of a large, representative population-based sample. Schizophr Bull (2014) 1.59
Psychosocial stress and psychosis. A review of the neurobiological mechanisms and the evidence for gene-stress interaction. Schizophr Bull (2008) 1.59
Structural and functional imaging studies in chronic cannabis users: a systematic review of adolescent and adult findings. PLoS One (2013) 1.59
Migration, ethnicity, and psychosis: toward a sociodevelopmental model. Schizophr Bull (2010) 1.58
Cannabis use disorders in schizophrenia: effects on cognition and symptoms. Schizophr Res (2010) 1.55
The association between delusional-like experiences, and tobacco, alcohol or cannabis use: a nationwide population-based survey. BMC Psychiatry (2011) 1.54
Association of pre-onset cannabis, alcohol, and tobacco use with age at onset of prodrome and age at onset of psychosis in first-episode patients. Am J Psychiatry (2009) 1.49
No detectable association between frequency of marijuana use and health or healthcare utilization among primary care patients who screen positive for drug use. J Gen Intern Med (2013) 1.49
Association of cannabis use with hospital admission and antipsychotic treatment failure in first episode psychosis: an observational study. BMJ Open (2016) 1.48
Epigenetic mediation of environmental influences in major psychotic disorders. Schizophr Bull (2009) 1.47
Psychosis as a transdiagnostic and extended phenotype in the general population. World Psychiatry (2016) 1.45
Gender differences in adolescent marijuana use and associated psychosocial characteristics. J Addict Med (2011) 1.42
Cannabis and psychosis/schizophrenia: human studies. Eur Arch Psychiatry Clin Neurosci (2009) 1.37
Gene-environment interplay between cannabis and psychosis. Schizophr Bull (2008) 1.34
Medical marijuana laws and suicides by gender and age. Am J Public Health (2014) 1.33
Adolescent cannabis use and psychosis: epidemiology and neurodevelopmental models. Br J Pharmacol (2010) 1.33
The impact of cannabis use on cognitive functioning in patients with schizophrenia: a meta-analysis of existing findings and new data in a first-episode sample. Schizophr Bull (2010) 1.32
Role of individual, peer and family factors in the use of cannabis and other illicit drugs: a longitudinal analysis among Finnish adolescent twins. Drug Alcohol Depend (2008) 1.31
Rate of cannabis use disorders in clinical samples of patients with schizophrenia: a meta-analysis. Schizophr Bull (2009) 1.30
Developing public health regulations for marijuana: lessons from alcohol and tobacco. Am J Public Health (2014) 1.30
Urbanicity, social adversity and psychosis. World Psychiatry (2013) 1.29
Does heavy adolescent marijuana use lead to criminal involvement in adulthood? Evidence from a multiwave longitudinal study of urban African Americans. Drug Alcohol Depend (2010) 1.22
Treatment of substance abusing patients with comorbid psychiatric disorders. Addict Behav (2011) 1.22
Genome-wide DNA methylation analysis of human brain tissue from schizophrenia patients. Transl Psychiatry (2014) 1.22
Medical marijuana: clearing away the smoke. Open Neurol J (2012) 1.21
Prevalence of psychotic symptoms and their risk factors in urban Tanzania. Int J Environ Res Public Health (2010) 1.20
Postnatal developmental trajectories of neural circuits in the primate prefrontal cortex: identifying sensitive periods for vulnerability to schizophrenia. Schizophr Bull (2011) 1.20
Gamma oscillation deficits and the onset and early progression of schizophrenia. Harv Rev Psychiatry (2010) 1.17
Gone to Pot - A Review of the Association between Cannabis and Psychosis. Front Psychiatry (2014) 1.14
Temporal association of cannabis use with symptoms in individuals at clinical high risk for psychosis. Schizophr Res (2008) 1.13
Differential developmental trajectories for CB1 cannabinoid receptor expression in limbic/associative and sensorimotor cortical areas. Synapse (2011) 1.13
Genetic predisposition to schizophrenia associated with increased use of cannabis. Mol Psychiatry (2014) 1.13
Spontaneous regression of septum pellucidum/forniceal pilocytic astrocytomas--possible role of Cannabis inhalation. Childs Nerv Syst (2011) 1.13
Amphetamine-induced psychosis--a separate diagnostic entity or primary psychosis triggered in the vulnerable? BMC Psychiatry (2012) 1.12
Identifying gene-environment interactions in schizophrenia: contemporary challenges for integrated, large-scale investigations. Schizophr Bull (2014) 1.10
Relationship of cannabinoid CB1 receptor and cholecystokinin immunoreactivity in monkey dorsolateral prefrontal cortex. Neuroscience (2010) 1.10
Gene-environment interactions in severe mental illness. Front Psychiatry (2014) 1.09
Altered cortical expression of GABA-related genes in schizophrenia: illness progression vs developmental disturbance. Schizophr Bull (2013) 1.09
Cannabis use and the risk of developing a psychotic disorder. World Psychiatry (2008) 1.08
Does Cannabidiol Protect Against Adverse Psychological Effects of THC? Front Psychiatry (2013) 1.08
Probability and predictors of the cannabis gateway effect: a national study. Int J Drug Policy (2014) 1.07
Clinical applications of schizophrenia genetics: genetic diagnosis, risk, and counseling in the molecular era. Appl Clin Genet (2012) 1.07
State of the art treatments for cannabis dependence. Psychiatr Clin North Am (2012) 1.07
Substance use in clinical high risk for psychosis: a review of the literature. Early Interv Psychiatry (2013) 1.06
A reexamination of medical marijuana policies in relation to suicide risk. Drug Alcohol Depend (2015) 1.05
Stress and neurodevelopmental processes in the emergence of psychosis. Neuroscience (2013) 1.05
Immunodensity and mRNA expression of A2A adenosine, D2 dopamine, and CB1 cannabinoid receptors in postmortem frontal cortex of subjects with schizophrenia: effect of antipsychotic treatment. Psychopharmacology (Berl) (2009) 1.05
"Time for dabs": Analyzing Twitter data on marijuana concentrates across the U.S. Drug Alcohol Depend (2015) 1.05
Cortical circuit dysfunction and cognitive deficits in schizophrenia--implications for preemptive interventions. Eur J Neurosci (2012) 1.04
A classification of sociomedical health indicators: perspectives for health administrators and health planners. Int J Health Serv (1976) 1.04
Do we have any solid evidence of clinical utility about the pathophysiology of schizophrenia? World Psychiatry (2011) 1.04
Marijuana use trajectories during the post-college transition: health outcomes in young adulthood. Drug Alcohol Depend (2012) 1.03
Dopamine release in chronic cannabis users: a [11c]raclopride positron emission tomography study. Biol Psychiatry (2012) 1.03
Cannabis users differ from non-users on measures of personality and schizotypy. Psychiatry Res (2011) 1.02
Keep off the grass? Cannabis, cognition and addiction. Nat Rev Neurosci (2016) 1.01
Legal highs: staying on top of the flood of novel psychoactive substances. Ther Adv Psychopharmacol (2015) 1.01
Role of cannabis and endocannabinoids in the genesis of schizophrenia. Psychopharmacology (Berl) (2009) 1.01
A positive association between anxiety disorders and cannabis use or cannabis use disorders in the general population--a meta-analysis of 31 studies. BMC Psychiatry (2014) 1.01
Cannabinoid receptor 1 gene polymorphisms and marijuana misuse interactions on white matter and cognitive deficits in schizophrenia. Schizophr Res (2011) 1.01
Contributions of endocannabinoid signaling to psychiatric disorders in humans: genetic and biochemical evidence. Neuroscience (2011) 1.01
The impact of substance use on brain structure in people at high risk of developing schizophrenia. Schizophr Bull (2010) 1.00
Early cannabis use and estimated risk of later onset of depression spells: Epidemiologic evidence from the population-based World Health Organization World Mental Health Survey Initiative. Am J Epidemiol (2010) 1.00
Chronic adolescent marijuana use as a risk factor for physical and mental health problems in young adult men. Psychol Addict Behav (2015) 1.00
Prospective study of cannabis use in adolescents at clinical high risk for psychosis: impact on conversion to psychosis and functional outcome. Psychol Med (2012) 1.00
The role of cannabis in cognitive functioning of patients with schizophrenia. Psychopharmacology (Berl) (2009) 0.99
Sativex long-term use: an open-label trial in patients with spasticity due to multiple sclerosis. J Neurol (2012) 0.99
Spontaneous object recognition and its relevance to schizophrenia: a review of findings from pharmacological, genetic, lesion and developmental rodent models. Psychopharmacology (Berl) (2011) 0.99
Delta-9-tetrahydrocannabinol-induced dopamine release as a function of psychosis risk: 18F-fallypride positron emission tomography study. PLoS One (2013) 0.98
Brief intervention addressing excessive cannabis use in young people consulting their GP: a pilot study. Br J Gen Pract (2009) 0.98
The effect of cannabis use and cognitive reserve on age at onset and psychosis outcomes in first-episode schizophrenia. Schizophr Bull (2011) 0.97
Conditional substance abuse and dependence by diagnosis of mood or anxiety disorder or schizophrenia in the U.S. population. Drug Alcohol Depend (2011) 0.97
Fibroblast growth factors in schizophrenia. Schizophr Bull (2009) 0.95
The prevention of schizophrenia. Schizophr Bull (2010) 0.95
Adversity, cannabis use and psychotic experiences: evidence of cumulative and synergistic effects. Br J Psychiatry (2014) 0.94
A familial risk enriched cohort as a platform for testing early interventions to prevent severe mental illness. BMC Psychiatry (2014) 0.94
Identification of loci associated with schizophrenia by genome-wide association and follow-up. Nat Genet (2008) 10.52
Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Arch Gen Psychiatry (2006) 9.44
Left ventricular assist device and drug therapy for the reversal of heart failure. N Engl J Med (2006) 8.98
Genetic relationship between five psychiatric disorders estimated from genome-wide SNPs. Nat Genet (2013) 8.02
A mega-analysis of genome-wide association studies for major depressive disorder. Mol Psychiatry (2012) 6.34
Facilitated physical activity as a treatment for depressed adults: randomised controlled trial. BMJ (2012) 5.61
Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev (2013) 5.57
Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev (2011) 5.30
Oligodendrocyte dysfunction in schizophrenia and bipolar disorder. Lancet (2003) 4.84
Multiple risk factor interventions for primary prevention of coronary heart disease. Cochrane Database Syst Rev (2011) 4.71
Obstetric complications and schizophrenia: historical and meta-analytic review. Am J Psychiatry (2002) 4.03
Therapist-delivered Internet psychotherapy for depression in primary care: a randomised controlled trial. Lancet (2009) 3.90
Why psychiatry can't afford to be neurophobic. Br J Psychiatry (2009) 3.80
Gene X environment interactions at the serotonin transporter locus. Biol Psychiatry (2008) 3.80
Randomised controlled trials investigating pharmacological and psychological interventions for treatment-refractory depression. Systematic review. Br J Psychiatry (2002) 3.72
Does alcohol increase the risk of overdose death: the need for a translational approach. Addiction (2008) 3.39
Heterogeneity in incidence rates of schizophrenia and other psychotic syndromes: findings from the 3-center AeSOP study. Arch Gen Psychiatry (2006) 3.35
Relapse prevention in schizophrenia with new-generation antipsychotics: a systematic review and exploratory meta-analysis of randomized, controlled trials. Am J Psychiatry (2003) 3.18
Treatment of postnatal depression in low-income mothers in primary-care clinics in Santiago, Chile: a randomised controlled trial. Lancet (2007) 3.03
Incidence of schizophrenia and other psychoses in ethnic minority groups: results from the MRC AESOP Study. Psychol Med (2006) 2.79
Self reported cannabis use as a risk factor for schizophrenia in Swedish conscripts of 1969: historical cohort study. BMJ (2002) 2.74
Randomized controlled trial of effect of prescription of clozapine versus other second-generation antipsychotic drugs in resistant schizophrenia. Schizophr Bull (2006) 2.71
Early detection and intervention evaluation for people at risk of psychosis: multisite randomised controlled trial. BMJ (2012) 2.70
The use of psychotropic medication in patients with emotionally unstable personality disorder under the care of UK mental health services. J Clin Psychiatry (2015) 2.67
A longitudinal study of premorbid IQ Score and risk of developing schizophrenia, bipolar disorder, severe depression, and other nonaffective psychoses. Arch Gen Psychiatry (2004) 2.65
Resuscitation at birth and cognition at 8 years of age: a cohort study. Lancet (2009) 2.57
Outcomes of conduct problems in adolescence: 40 year follow-up of national cohort. BMJ (2009) 2.47
Violence against women by their intimate partner during pregnancy and postnatal depression: a prospective cohort study. Lancet (2010) 2.46
Detection of depression and anxiety in primary care: follow up study. BMJ (2002) 2.44
Extrapyramidal motor side-effects of first- and second-generation antipsychotic drugs. Br J Psychiatry (2012) 2.41
Severe disease expression of cardiac troponin C and T mutations in patients with idiopathic dilated cardiomyopathy. J Am Coll Cardiol (2004) 2.40
Paternal age and risk for schizophrenia. Br J Psychiatry (2003) 2.34
Disease-relevant autoantibodies in first episode schizophrenia. J Neurol (2010) 2.33
Incidence of schizophrenia and other psychoses in England, 1950-2009: a systematic review and meta-analyses. PLoS One (2012) 2.33
A qualitative study exploring how GPs decide to prescribe antidepressants. Br J Gen Pract (2005) 2.31
The histologic basis of late gadolinium enhancement cardiovascular magnetic resonance in hypertrophic cardiomyopathy. J Am Coll Cardiol (2004) 2.31
Paternal age and schizophrenia: a population based cohort study. BMJ (2004) 2.27
If cannabis caused schizophrenia--how many cannabis users may need to be prevented in order to prevent one case of schizophrenia? England and Wales calculations. Addiction (2009) 2.25
Examining interactions between risk factors for psychosis. Br J Psychiatry (2010) 2.25
Cannabis and schizophrenia: model projections of the impact of the rise in cannabis use on historical and future trends in schizophrenia in England and Wales. Addiction (2007) 2.20
Psychotic experiences and psychotic disorders at age 18 in relation to psychotic experiences at age 12 in a longitudinal population-based cohort study. Am J Psychiatry (2013) 2.17
Group art therapy as an adjunctive treatment for people with schizophrenia: multicentre pragmatic randomised trial. BMJ (2012) 2.17
Schizophrenia in the offspring of antenatally depressed mothers in the northern Finland 1966 birth cohort: relationship to family history of psychosis. Am J Psychiatry (2009) 2.11
Fetal growth and childhood behavioral problems: results from the ALSPAC cohort. Am J Epidemiol (2006) 2.09
A quantitative meta-analysis of population-based studies of premorbid intelligence and schizophrenia. Schizophr Res (2011) 2.09
Cross-national clinical and functional remission rates: Worldwide Schizophrenia Outpatient Health Outcomes (W-SOHO) study. Br J Psychiatry (2011) 2.06
Raised incidence rates of all psychoses among migrant groups: findings from the East London first episode psychosis study. Arch Gen Psychiatry (2008) 1.96
Violence and psychiatric morbidity in a national household population--a report from the British Household Survey. Am J Epidemiol (2006) 1.94
Reliability and comparability of psychosis patients' retrospective reports of childhood abuse. Schizophr Bull (2009) 1.94
Obsessive-compulsive disorder: prevalence, comorbidity, impact, and help-seeking in the British National Psychiatric Morbidity Survey of 2000. Am J Psychiatry (2006) 1.93
Self-help books for depression: how can practitioners and patients make the right choice? Br J Gen Pract (2005) 1.91
Stigma revisited, disclosure of emotional problems in primary care consultations in Wales. Soc Sci Med (2003) 1.84
Prospective study of peer victimization in childhood and psychotic symptoms in a nonclinical population at age 12 years. Arch Gen Psychiatry (2009) 1.81
Guidelines for autopsy investigation of sudden cardiac death. Virchows Arch (2007) 1.81
The patient-doctor relationship: a synthesis of the qualitative literature on patients' perspectives. Br J Gen Pract (2009) 1.80
Systematic review: accuracy of anti-citrullinated Peptide antibodies for diagnosing rheumatoid arthritis. Ann Intern Med (2010) 1.78
Increased pituitary volume in antipsychotic-free and antipsychotic-treated patients of the AEsop first-onset psychosis study. Neuropsychopharmacology (2005) 1.76
Contribution of common genetic variants to antidepressant response. Biol Psychiatry (2012) 1.73
Psychosis, victimisation and childhood disadvantage: evidence from the second British National Survey of Psychiatric Morbidity. Br J Psychiatry (2004) 1.72
Self-harm in first-episode psychosis. Br J Psychiatry (2008) 1.72
Substance use in a population-based clinic sample of people with first-episode psychosis. Br J Psychiatry (2007) 1.71
Pathology of pulmonary antibody-mediated rejection: 2012 update from the Pathology Council of the ISHLT. J Heart Lung Transplant (2013) 1.71
Infant developmental milestones and subsequent cognitive function. Ann Neurol (2007) 1.69
Negative self-schemas and the onset of depression in women: longitudinal study. Br J Psychiatry (2005) 1.69
Developmental typology of trajectories to nighttime bladder control: epidemiologic application of longitudinal latent class analysis. Am J Epidemiol (2003) 1.65
Parental socioeconomic status and risk of offspring autism spectrum disorders in a Swedish population-based study. J Am Acad Child Adolesc Psychiatry (2012) 1.65
IQ and non-clinical psychotic symptoms in 12-year-olds: results from the ALSPAC birth cohort. Br J Psychiatry (2008) 1.64
Alcohol consumption as a risk factor for anxiety and depression: results from the longitudinal follow-up of the National Psychiatric Morbidity Survey. Br J Psychiatry (2005) 1.63
Evidence that interaction between neuregulin 1 and its receptor erbB4 increases susceptibility to schizophrenia. Am J Med Genet B Neuropsychiatr Genet (2006) 1.61
Adolescent alcohol and tobacco use and early socioeconomic position: the ALSPAC birth cohort. Pediatrics (2011) 1.60
Clinical effectiveness of collaborative care for depression in UK primary care (CADET): cluster randomised controlled trial. BMJ (2013) 1.56
Childhood conduct disorder trajectories, prior risk factors and cannabis use at age 16: birth cohort study. Addiction (2013) 1.56
The association between early autistic traits and psychotic experiences in adolescence. Schizophr Res (2012) 1.55
Inclusion of methodological filters in searches for diagnostic test accuracy studies misses relevant studies. J Clin Epidemiol (2010) 1.55
Epilepsy and psychiatric comorbidity: a nationally representative population-based study. Epilepsia (2012) 1.54
Childhood cognitive ability and adult mental health in the British 1946 birth cohort. Soc Sci Med (2007) 1.54
Starting dose is a risk factor for allopurinol hypersensitivity syndrome: a proposed safe starting dose of allopurinol. Arthritis Rheum (2012) 1.54
Self-reported psychotic symptoms in the general population: results from the longitudinal study of the British National Psychiatric Morbidity Survey. Br J Psychiatry (2006) 1.54
Forty-year psychiatric outcomes following assessment for internalizing disorder in adolescence. Am J Psychiatry (2007) 1.54
Effects of cannabis use on outcomes of psychotic disorders: systematic review. Br J Psychiatry (2008) 1.53
Maternal depression during pregnancy and the postnatal period: risks and possible mechanisms for offspring depression at age 18 years. JAMA Psychiatry (2013) 1.52
Practitioner review: A critical perspective on gene-environment interaction models--what impact should they have on clinical perceptions and practice? J Child Psychol Psychiatry (2014) 1.51
Pre-conception inter-pregnancy interval and risk of schizophrenia. Br J Psychiatry (2011) 1.51
Biomarkers for detecting thiamine deficiency--improving confidence and taking a comprehensive history are also important. Alcohol Alcohol (2009) 1.50
Socio-economic position and common mental disorders. Longitudinal study in the general population in the UK. Br J Psychiatry (2006) 1.48
Ethnic differences in prisoners. 1: criminality and psychiatric morbidity. Br J Psychiatry (2002) 1.48
A longitudinal typology of symptoms of depression and anxiety over the life course. Biol Psychiatry (2007) 1.47